These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 20704946)

  • 1. Mutations of EGFR in lung cancers and their implications for targeted therapy.
    Shigematsu H; Gazdar AF
    Discov Med; 2004 Dec; 4(24):444-7. PubMed ID: 20704946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular analysis of the erbB gene family calmodulin-binding and calmodulin-like domains in astrocytic gliomas.
    Arjona D; Bello MJ; Alonso ME; Gonzalez-Gomez P; Lomas J; Aminoso C; Lopez-Marin I; Isla A; De Campos JM; Vaquero J; Gutierrez M; Villalobo A; Rey JA
    Int J Oncol; 2004 Nov; 25(5):1489-94. PubMed ID: 15492843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
    Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
    Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.
    Naresh A; Long W; Vidal GA; Wimley WC; Marrero L; Sartor CI; Tovey S; Cooke TG; Bartlett JM; Jones FE
    Cancer Res; 2006 Jun; 66(12):6412-20. PubMed ID: 16778220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of HER2/neu in tumor progression and therapy.
    Ménard S; Casalini P; Campiglio M; Pupa SM; Tagliabue E
    Cell Mol Life Sci; 2004 Dec; 61(23):2965-78. PubMed ID: 15583858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ErbB/HER receptor protein-tyrosine kinases and cancer.
    Roskoski R
    Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase.
    Hobbs SS; Cameron EM; Hammer RP; Le AT; Gallo RM; Blommel EN; Coffing SL; Chang H; Riese DJ
    Oncogene; 2004 Jan; 23(4):883-93. PubMed ID: 14661053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
    Witton CJ; Reeves JR; Going JJ; Cooke TG; Bartlett JM
    J Pathol; 2003 Jul; 200(3):290-7. PubMed ID: 12845624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The upgraded role of HER3 and HER4 receptors in breast cancer.
    Koutras AK; Fountzilas G; Kalogeras KT; Starakis I; Iconomou G; Kalofonos HP
    Crit Rev Oncol Hematol; 2010 May; 74(2):73-8. PubMed ID: 19481955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review.
    Patnaik SK; Chandrasekar MJN; Nagarjuna P; Ramamurthi D; Swaroop AK
    Mini Rev Med Chem; 2022 Oct; 22(22):2831-2846. PubMed ID: 35549881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of ErbB Receptor Family Tyrosyl Phosphorylation in Ovarian Carcinoma Cells.
    Hamburger AW
    Methods Mol Med; 2001; 39():571-5. PubMed ID: 21340814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptides for Dual Targeting of ErbB1 and ErbB2: Blocking EGFR Cell Signaling Transduction Pathways for Cancer Chemotherapy.
    Patnaik SK; Swaroop AK; Nagarjuna P; Nanjan MJ; Chandrasekar MJN
    Curr Mol Pharmacol; 2024; 17(1):e240223214012. PubMed ID: 36843255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials.
    Maennling AE; Tur MK; Niebert M; Klockenbring T; Zeppernick F; Gattenlöhner S; Meinhold-Heerlein I; Hussain AF
    Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31756933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER3 signaling and targeted therapy in cancer.
    Mishra R; Patel H; Alanazi S; Yuan L; Garrett JT
    Oncol Rev; 2018 Jan; 12(1):355. PubMed ID: 30057690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Protein Levels of the Receptor Tyrosine Kinase ErbB3 in Serum.
    D'Abronzo LS; Pan CX; Ghosh PM
    Methods Mol Biol; 2018; 1655():319-334. PubMed ID: 28889394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the biology of HER3 receptor as a therapeutic target in human cancer.
    Lyu H; Han A; Polsdofer E; Liu S; Liu B
    Acta Pharm Sin B; 2018 Jul; 8(4):503-510. PubMed ID: 30109175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR signaling in breast cancer: bad to the bone.
    Foley J; Nickerson NK; Nam S; Allen KT; Gilmore JL; Nephew KP; Riese DJ
    Semin Cell Dev Biol; 2010 Dec; 21(9):951-60. PubMed ID: 20813200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer.
    Kripp M; Merx K; Wirtz RM; Gaiser T; Eidt S; Schwaab J; Post S; Wenz F; Hochhaus A; Hofheinz RD; Erben P
    Gastroenterol Res Pract; 2016; 2016():3481578. PubMed ID: 27610130
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.